Company: BKYI
Filing Date: 2025-12-02
Form Type: 424B3
Source: 0001437749-25-036669
Chunk: 11

Company: BIO KEY INTERNATIONAL INC
Filing Date: 2025-12-02
Form: 424B3
Chunk 11
---
 to $1.02 per share.

In consideration for the exercise of the Existing Warrants, subject to compliance with the beneficial ownership limitations included in the Existing Warrants, and the payment by the selling stockholder of the combined purchase price of $0.25 per Existing Warrant (the “New Warrant Consideration”), the selling stockholder received the Warrants to purchase up to an aggregate of 6,183,336 shares of our common stock.

The Warrants are immediately exercisable at an exercise price of $1.02 per share and will expire five years from the date of issuance. We agreed to file a resale registration statement covering the public resale of the shares of common stock issuable upon exercise of the Warrants with the SEC, and to use commercially reasonable efforts to have such resale registration statement declared effective by the SEC within 90 calendar days following the date of the Warrant Exercise Agreement. The Warrants include a beneficial ownership limitation that prevents the selling stockholder from beneficially owning more than 4.99% of our outstanding common stock at any time.

The gross proceeds to us from the exercise of the Existing Warrants were approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses. Maxim Group LLC acted as the exclusive placement agent in connection with the Warrant Exercise Agreement and received a cash fee equal to 6.0% of the gross proceeds. The closing pursuant to the Warrant Exercise Agreement occurred on October 27, 2025. We intend to use the net proceeds for working capital and general corporate purposes, including repayment of a portion of our outstanding secured note.

<div align='center'>USE OF PROCEEDS</div>

The selling stockholder will receive all proceeds from the sale of the shares of common stock offered hereby. We will not receive any proceeds from the sale of common stock by the selling stockholder.

We will, however, receive cash proceeds equal to the exercise price of the Warrants. Accordingly, we may receive aggregate gross proceeds of $6,307,002.72 assuming that the Warrants are exercised in full at an exercise price of $1.02 per share. We expect to use any proceeds received by us from the exercise of the Warrants for working capital and general corporate purposes, including repayment of all or a portion of our outstanding secured note.

We will bear all costs, expenses and fees in connection with the registration of the shares, including, without limitation, all registration and filing fees and fees and expenses of our counsel and our accountants